Article Text

Download PDFPDF
ECM1: a novel matricellular protein with promising antifibrotic potential
  1. Isabel Fabregat1,2,
  2. Francisco Javier Cubero2,3,4
  1. 1TGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de L'Hospitalet, Barcelona, Spain
  2. 2Centre for Biomedical Research, Network on Liver and Digestive Diseases (CIBEREHD), Madrid, Spain
  3. 3Immunology, Ophthalmology and ENT, Complutense University of Madrid Faculty of Medicine, Madrid, Spain
  4. 4Health Research Institute Gregorio Marañón (IiSGM), Madrid, Spain
  1. Correspondence to Professor Francisco Javier Cubero; fcubero{at}ucm.es

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Although numerous compounds that target individual or multiple cells or pathways have demonstrated antifibrotic potential, the reality is that only a small number of candidates have progressed successfully to the clinical trials phase. It seems plausible that the development of antifibrotic therapies focusing on the removal of fibrosis-causing agents and factors affecting hepatic stellate cell (HSC) activation might hold promise for reducing and preventing liver disease. Moreover, these therapies need to be safe with little or no hepatotoxicity and/or adverse effects.

In liver homoeostasis, transforming growth factor-beta (TGF-β) is secreted in a biologically inactive, the so-called latent TGF-β form (LTGF-β) associated in a non-covalent complex with the extracellular matrix (ECM).1 In response to injury, local LTGF-β complexes are converted into active TGF-β. Activation of LTGF-β is mediated by several signals, including integrins, thrombospondin, proteases and reactive oxygen species.2 During liver fibrosis, TGF-β acts as a master profibrogenic cytokine in promoting activation and myofibroblastic differentiation of HSC, a central event in liver fibrogenesis and ECM production.3 Therefore, the regulation of locally activated TGF-β levels might be an excellent therapeutic target for liver fibrogenesis.

ECM protein-1 (ECM1) was recently identified2 as a critical gatekeeper in the healthy liver, contributing to normal architecture and physiological homoeostasis of cell–cell communication by …

View Full Text

Footnotes

  • X @IsabelFabregat, @CUBEROlab

  • Contributors IF and FJC wrote the draft and the final version of the manuscript.

  • Funding This work was supported by the MICINN Retos MICIU/AEI/10.13039/501100011033, PID2020-117941RB-I00, EXOHEP2-CM (S2022/BMD-7409) and HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Hepatology
    Frederik Link Yujia Li Jieling Zhao Stefan Munker Weiguo Fan Zeribe C Nwosu Ye Yao Shanshan Wang Chenjun Huang Roman Liebe Seddik Hammad Hui Liu Chen Shao Chunfang Gao Bing Sun Natalie J Török Huiguo Ding Matthias PA Ebert Honglei Weng Peter ten Dijke Dirk Drasdo Steven Dooley Sai Wang